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Background—Although pharmacological block of the slow, delayed rectifier potassium current (IKs) by chromanol 293B,
L-735,821, or HMR-1556 produces little effect on action potential duration (APD) in isolated rabbit and dog ventricular
myocytes, the effect of IKs block on normal human ventricular muscle APD is not known. Therefore, studies were
conducted to elucidate the role of IKs in normal human ventricular muscle and in preparations in which both
repolarization reserve was attenuated and sympathetic activation was increased by exogenous dofetilide and adrenaline.
Methods and Results—Preparations were obtained from undiseased organ donors. Action potentials were measured in
ventricular trabeculae and papillary muscles using conventional microelectrode techniques; membrane currents were
measured in ventricular myocytes using voltage-clamp techniques. Chromanol 293B (10 mol/L), L-735,821 (100
nmol/L), and HMR-1556 (100 nmol/L and 1 mol/L) produced a 12-ms change in APD while pacing at cycle lengths
ranging from 300 to 5000 ms, whereas the IKr blockers sotalol and E-4031 markedly lengthened APD. In voltage-clamp
experiments, L-735,821 and chromanol 293B each blocked IKs in the presence of E-4031 to block IKr. The
E-4031–sensitive current (IKr) at the end of a 150-ms-long test pulse to 30 mV was 32.96.7 pA (n8); the
L-735,821–sensitive current (IKs) magnitude was 17.82.94 pA (n10). During a longer 500-ms test pulse, IKr was not
substantially changed (33.66.1 pA; n8), and IKs was significantly increased (49.67.24 pA; n10). On application
of an “action potential–like” test pulse, IKr increased as voltage became more negative, whereas IKs remained small
throughout all phases of the action potential–like test pulse. In experiments in which APD was first lengthened by 50
nmol/L dofetilide and sympathetic activation was increased by 1 mol/L adrenaline, 1 mol/L HMR-1556 significantly
increased APD by 14.73.2% (P0.05; n3).
Conclusions—Pharmacological IKs block in the absence of sympathetic stimulation plays little role in increasing normal
human ventricular muscle APD. However, when human ventricular muscle repolarization reserve is attenuated, IKs plays
an increasingly important role in limiting action potential prolongation. (Circulation. 2005;112:1392-1399.)
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Action potential repolarization is an important phenome-non in the heart where it controls action potential
duration (APD) and thus affects refractoriness and conduc-
tion of electrical impulses throughout the heart. Several
pharmacological agents intended to abate cardiac arrhythmias
specifically target mechanisms that regulate APD. In the
ventricles, APD, in large part, determines dynamic changes in
QT duration on a beat-by-beat basis.
See p 1376
The rapid component of the delayed rectifier potassium
current (IKr) has been identified in several mammalian spe-
cies,1–3 including humans,4–7 and pharmacological agents that
selectively block IKr (eg, E-4031, sotalol, and dofetilide)
markedly increase APD, QT duration, and ventricular refrac-
toriness. As such, high doses of these IKr blockers are
associated with induction of torsade de pointes.8,9 In addition,
mutations in ion channel genes (eg, HERG and KCNE2) that
suppress IKr are associated with the inherited long-QT syn-
drome LQT2, which is linked to an increased incidence of
sudden cardiac death.10 As such, IKr plays a major role in
regulation of action potential repolarization and is important
in the maintenance of normal heart rhythms; loss of this
current is highly arrhythmogenic.11
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The role of the slow delayed rectifier potassium current
(IKs) in human ventricular muscle action potential repolariza-
tion, on the other hand, has been debated. As with IKr, IKs has
been identified in several mammalian species,1–3 including
humans,6,12 and mutations in KCNQ1 and KCNE1, the - and
-subunits of the IKs potassium channel, are associated with
another specific form of the inherited long-QT syndrome,
LQT1.10 However, we have previously demonstrated that
complete pharmacological block of IKs by either chromanol
293B or L-735,821 has little effect on APD in isolated dog
and rabbit ventricular muscle11,13 over a wide range of
physiological pacing frequencies. These findings led us to
speculate that IKs normally plays little role in ventricular
muscle action potential repolarization, but when APD is
abnormally long, IKs likely provides an important safety
mechanism that, when removed, increases arrhythmic
risk.11,13 Other investigators have confirmed these previous
findings,14 and computer simulations supported speculation
that IKs plays little role in adaptations of APD to changes in
heart rate.15 The role of IKs in human ventricular muscle,
however, remains controversial despite our preliminary char-
acterizations of IKr7 and IKs12 in isolated human ventricular
myocytes that suggest that both currents behave similarly as
in isolated dog2,11 and rabbit3,13 ventricular myocytes. Thus,
the purpose of the present study was to confirm our initial
findings while elucidating the role of IKs in normal human
ventricular muscle action potential repolarization in the ab-
sence of tonic sympathetic stimulation.
Preliminary results of this work were presented at the 1999
Annual Scientific Session of the American Heart Association.16
Methods
Patients
Hearts obtained from organ donors were explanted to obtain pulmo-
nary and aortic valves for transplant surgery. Before cardiac explan-
tation, organ donor patients did not receive medication except
dobutamine, furosemide, and plasma expanders. The investigations
conform to the principles outlined in the Declaration of Helsinki
(Cardiovascular Research 1997, 35:2 to 35:4), and all experimental
protocols were approved by the Albert Szent-Györgyi Medical Univer-
sity Ethical Review Board (No. 51–57/1997 OEj). Proper consent was
obtained for use of each individual’s tissue for experimentation.
Action Potential Measurements in
Multicellular Preparations
Tissue Preparation
Action potentials were recorded in ventricular trabeculae and papil-
lary muscle preparations (2 mm in diameter; n45) obtained from
the right ventricles of 26 undiseased human donor hearts (from 17
men, 9 women; age, 41.74.1 years) using conventional microelec-
trode techniques. After explantation, each heart was perfused with
cardioplegic solution and kept cold (4°C to 6°C) for 2 to 4 hours before
dissection. Trabeculae and papillary muscles were then excised and
mounted in a tissue chamber (volume,50 mL) perfused with oxygen-
ated (95% O25% CO2) modified Tyrode’s solution containing
(in mmol/L) NaCl 115, KCl 4, CaCl2 1.8, MgCl 1, NaHCO3 20, and
glucose 11. The pH of this solution was 7.35 to 7.45 at 37°C.
Protocol
Initially, each preparation was stimulated at a basic cycle length of
1000 ms (frequency, 1 Hz) using 2-ms-long rectangular constant-
voltage pulses isolated from ground and delivered via bipolar
platinum electrodes in contact with the preparation using an EMG
4767 type of stimulator (Medicor Ltd). One hour or more was
allowed for each preparation to equilibrate while continuously
superfused with Tyrode’s solution warmed to 37°C. Transmembrane
potentials were recorded using a conventional glass microelectrode
filled with 3 mol/L KCl with a tip resistance of 5 to 20 mol/L
connected to an high-impedance electrometer (Bio-Logic VF102,
CLAIX, F-38640) referenced to ground. The first derivative of
transmembrane potential (Vmax) was electronically obtained using a
Bio-Logic DV-140 (Claix, F-38640) differentiator designed and
calibrated to have a linear response over the range of 10 to 1000 V/s.
Amplifier outputs were digitized with an ADA 3300 analog-to-digital
converter (Real Time Devices Inc) with a maximum sampling fre-
quency of 50 kHz connected to an IBM-compatible personal computer.
Data were stored and analyzed on a personal computer while being
monitored on a dual-beam memory oscilloscope (Tektronix 2230).
Resting membrane potential, action potential amplitude, and APD,
measured at 50% and 90% repolarization (APD50 and APD90), were
automatically measured with software developed in our laboratory
(APES, Hugo Sachs Elektronik, March-Hugstetten). Stimulation pulses
were also controlled by PC software providing constant-current pulses
with programmed timing and amplitudes to the preparation via a EMG
47671 type of signal isolator (Medicor Ltd, Budapest).
In each experiment, baseline action potential characteristics were
first obtained during superfusion with normal 37°C Tyrode’s solu-
tion during continuous pacing at a basic cycle length of 1000 ms,
followed by a run of changing pacing cycle lengths (300, 400, 500,
700, 1000, 1500, 2000, 3000, and 5000 ms) sequentially applied for
25 beats each. This procedure allowed action potential parameters to
be quickly obtained at each pacing cycle length after a “quasi-steady
state” was established. Recordings were continuously monitored to
confirm 1-to-1 activation throughout the procedure.
After baseline measurements were obtained, each preparation was
superfused with Tyrode’s solution containing a single test drug
diluted to the proper concentration for 40 to 60 minutes before
measurements were repeated at 3-minute intervals in the continued
presence of the test drug until a 5% change occurred in action
potential characteristics between subsequent samples. When micro-
electrode impalement was lost, reimpalement was attempted. If
action potential characteristics recorded with the new impalement
deviated by 5% from the preceding ones, the experiment was
terminated, and results were excluded from evaluation.
Drugs Used
The IKr blockers d-sotalol (Bristol-Myers Squibb Co) and E-4031
(Institute for Drug Research Ltd) were prepared daily from aqueous
stock solutions (30 and 10 mmol/L, respectively). Similarly, the IKs
blockers chromanol 293B (Aventis Pharma) and HMR-1556 (Aventis
Pharma) plus L-735,821 (Merck-Sharpe & Dohme Co) were diluted
from stock solutions (10 and 1 mmol/L, respectively) containing 100%
dimethyl sulfoxide. This procedure resulted in a 0.1% dimethyl sulfox-
ide concentration when the effects of the drugs were examined. This and
the lower dimethyl sulfoxide concentrations alone did not affect action
potential characteristics in separate studies.
Transmembrane Current Measurements
Cell Isolation
Ventricular myocytes were enzymatically dissociated from 7 human
hearts (3 male donors, 4 female donors; age, 41.555.7 years). After
explantation, hearts were transported to the laboratory in cold (4°C)
cardioplegic solution. A portion of the left ventricular wall was
excised with an attached branch of the left descending coronary
artery, which was cannulated and mounted on a modified 60-cm-
high Langendorff perfusion apparatus. Each preparation was per-
fused with each of the following perfusates for the times indicated:
(1) normal Tyrode’s solutions, 10 minutes; (2) Ca2-free Tyrode’s
solution, 10 minutes, and (3) Ca2-free Tyrode’s solution containing
collagenase (type I, 0.66 mg/mL, Sigma-Aldrich Fine Chemicals),
elastase (type III, 0.045 mg/mL, Sigma-Aldrich Fine Chemicals),
taurine (50 mmol/L, Sigma-Aldrich Fine Chemicals), and BSA
(fraction V, fatty acid free, 2 mg/mL, Sigma-Aldrich Fine Chemi-
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cals), 15 minutes. After this series of perfusions, the dissociation
solution was supplemented with protease (type XIV, 0.12 mg/mL,
Sigma-Aldrich Fine Chemicals), and the tissue was perfused for an
additional 45 to 60 minutes. Portions of clearly digested left
ventricular wall were removed, minced into small pieces, and placed
into either Kraft-Brühe (KB) solution17 or Ca2-free Tyrode’s
solution supplemented CaCl2 (1.25 mmol/L) for 15 minutes. After
this period, the suspension of minced tissue was gently agitated in a
small beaker to obtain single cells. Although myocytes thus obtained
were of epicardial, midmyocardial, and endocardial origin, there was
no way to determine from which an individual cell was dissociated.
Throughout the isolation procedure, all solutions were oxygenated
with 100% O2 while their temperatures were maintained at 37°C.
After a suspension of isolated myocytes was obtained, individual
heart cells were allowed to settle to the bottom of the beaker for 10
minutes. Half of the supernatant was then replaced by fresh solution,
and the cells resuspended in the solution were allowed to settle. This
procedure was repeated 3 times to retard further enzymatic digestion.
Myocytes in KB solution were stored at 4°C, and those stored in
Tyrode’s solution were maintained at 12°C to 14°C.
Cell Isolation Solutions
The composition of each solution used for myocyte isolation was
(in mmol/L) as follows: (1) cardioplegic solution: NaCl 110, KCl 16,
MgCl2 16, CaCl2 1.2, and NaHCO3 10; (2) normal Tyrode’s solution:
NaCl 135, KCl 4.7, NaHCO3 4.4, KH2PO4 1.2, MgSO4 1.2, HEPES
10, glucose 10, and CaCl2 1.0 (pH 7.2 adjusted with NaOH); (3)
Ca2-free solution: NaCl 135, KCl 4.7, KH2PO4 1.2, MgSO4 1.2,
HEPES 10, NaHCO3 4.4, and glucose 10 (pH 7.2 adjusted with
NaOH); and (4) KB solution: KOH 90, L-glutamic acid 70, taurine
15, KCl 30, KH2PO4 10, MgCl2 0.5, HEPES 10, glucose 11, and
EGTA 0.5 (pH 7.3 adjusted with KOH).
Experimental Protocol
One drop of the myocyte suspension was placed in a 0.4-mL
transparent recording chamber mounted on the stage of an inverted
microscope (TMS, Nikon UK Ltd), and at least 5 minutes was
allowed for individual myocytes to settle and adhere to its bottom
before superfusion was initiated. Only rod-shaped, clearly striated
myocytes (average length, 100 m; diameter, 20 m; Cm, 210 F)
were used for recording. Although the yield varied greatly (from 5%
to 70%) between each dissociation procedure, the ease of electrode-
seal formation and the quality of the measurements obtained did not
correlate with yield. HEPES-buffered Tyrode’s solution was used as
the normal superfusate. This solution contained (in mmol/L) NaCl
144, NaH2PO4 0.33, KCl 4.0, CaCl2 1.8, MgCl2 0.53, glucose 5.5,
and HEPES 5.0 at pH 7.4. Superfusion was maintained by gravity
flow at 2 to 2.5 mL/min. Micropipettes were fabricated from
borosilicate glass capillaries (Clark Electromedical Instruments)
using a microprocessor-controlled horizontal puller (Sutter Instru-
ments). These electrodes had resistances between 1.5 and 2.5 M
when filled with a pipette solution containing (in mmol/L)
K-aspartate 100, KCl 20, MgATP 5, K4BAPTA 5, HEPES 10, and
glucose 5. The pH of the filling solution was adjusted to 7.2 by KOH.
BAPTA rather than EGTA was used in the pipette solution to
minimize the possible influence of the Na/Ca2 exchanger current.
The external solution contained 1 mol/L nisoldipine to completely
block the inward Ca2 current (ICa). The inward sodium current (INa)
was inactivated using a 40-mV holding potential, which also
largely inactivated the transient outward current (Ito). Membrane
currents were recorded with either an Axopatch-1D or an Axopatch
200B patch-clamp amplifier (Axon Instruments) in the whole-cell
patch-clamp configuration. After a high- (1 to 10 G) resistance seal
was established by gentle suction, the cell membrane beneath the
electrode tip was disrupted by additional suction or application of
1.5-V electrical pulses for 1 to 5 ms. Series resistance was typically
4 to 8 M before compensation (usually 50% to 80%). When the
initial series resistance was 10 M or when series resistance
increased substantially during measurement, the experiment was
terminated, and the results were excluded from analyses. Membrane
currents were digitized with a 333-kHz analog-to-digital converter
(Digidata 1200, Axon Instruments) under software control (pClamp
6.0 and pClamp7, Axon Instruments), and results were analyzed with
Axon software programs (pClamp 6.0 and plamp7.0, Axon Instru-
ments) after low-pass (1-kHz) filtration.
Statistical Analysis
Student t tests for paired data were used to compare results. Results
were considered significant at P0.05.
Results
Effects of IKs and IKr Blockade on Human
Ventricular Muscle APD
Concentrations of chromanol 293B (10 mol/L), L-735,821
(100 nmol/L), and HMR-1556 (100 nmol/L and 1 mol/L)
reported to selectively block IKs in cardiac ventricular muscle
preparations11–14,18,19 in other species produced a 9-ms
(2.8%) change in human ventricular papillary muscle APD
after 40 minutes of exposure during continuous pacing at a
cycle length of 1000 ms (Figure 1, top and middle). In
contrast, concentrations of d-sotalol (30 mol/L) and E-4031
(1 mol/L), expected to selectively block IKr11, markedly and
Figure 1. Human ventricular papillary muscle action potential
recordings in the absence of any sympathetic agonist before
and after 40 minutes of superfusion with the IKs blockers 10
mol/L chromanol 293B (top left), 100 nmol/L L-735,821 (top
right), and 100 nmol/L and 1 mol/L HMR-1556 (middle) and
the IKr blockers 1 mol/L E-4031 (bottom left) and 30 mol/L
d-sotalol (bottom right). Stimulation frequency was 1 Hz.
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significantly increased human ventricular muscle APD under
identical conditions (Figure 1, bottom). This difference in the
effects of chromanol 293 B (10 mol/L), L-735,821 (100
nmol/L), and HMR 1556 (100 nmol/L and 1 mol/L) compared
with d-sotalol (30 mol/L) and E-4031 (1 mol/L) on APD was
observed in human ventricular muscle over a wide range of
pacing cycle lengths (300 to 5000 ms) (Figure 2). Over this
range of pacing cycle lengths, chromanol 293B (Figure 2),
L-735,821, or HMR (100 nmol/L and 1 mol/L) produced a
change of 12 ms (3.2%) in APD, whereas d-sotalol and
E-4031 each markedly lengthened human ventricular APD in a
reverse frequency-dependent manner.
IKr and IKs Characterization in Undiseased Human
Ventricular Myocytes
Figure 3A illustrates the effects of 100 nmol/L L-735,821 and
30 mol/L chromanol 293B on IKs tail currents in isolated
human ventricular myocytes after 5000-ms-long test pulses to
between 0 and 50 mV from and return to a holding potential
of 40 mV in the presence of 1 mol/L E-4031. E-4031 was
added to completely inhibit IKr. L-735,821 (100 nmol/L) com-
pletely abolished IKs, whereas chromanol 293B (30 mol/L)
nearly did so. In other experiments, the selective IKr E-4031 (1
mol/L) alone completely blocked IKr tail currents (Figure 3B)
elicited by 1000-ms-long test pulses to between20 and 50 mV
from and to return to a holding potential of 40 mV.
The relative magnitude of IKs and IKr activated during a
standardized human ventricular action potential depolariza-
tion was estimated by comparing the amplitudes of the
L-735,821–sensitive (IKs) and E-4031–sensitive (IKr) currents
at the end of a 150-ms-long test pulse to 30 mV and their tail
currents on return to a 40 mV holding potential. This test
potential amplitude is slightly positive to the normal human
ventricular muscle action potential plateau, whereas the
holding potential used is representative of a voltage encoun-
tered during final action potential repolarization. Under these
conditions, IKs and IKr were measured by subtracting mem-
brane currents before and after 4 to 5 minutes of exposure to
L-735,821 (100 nmol/L) or E-4031 (1 mol/L), respectively.
The E-4031–sensitive current (IKr) amplitude at the end of the
150-ms-long test pulse was 32.96.7 pA (n8) or 27% of
the tail current amplitude measured after the voltage test
pulse returned to40 mV (119.916.6 pA; n8) (Figure 4A
and 4C). Under identical voltage-clamp conditions, the
L-735,821–sensitive current (IKs) during the test pulse to 30
mV was larger than its tail current on return to 40 mV
(Figure 4B and 4C). The magnitude of IKs during the test
pulse was 17.82.94 pA at 30 mV compared with 6.71.93
pA at 40 mV (n10) and approximately an order of
magnitude less than the IKr tail current.
When IKs and IKr were individually measured after 500-ms-
long test pulses to 30 mV and their values were compared
with those obtained above after a 150-ms test pulse to the
Figure 2. Frequency-dependent effect of IKr (by 1 mol/L
E-4031 or 30 mol/L sotalol) and IKs block (by 10 mol/L chro-
manol 293B, 100 nmol/L and 1 mol/L HMR-1556, or 100
nmol/L L-735,821) on APD in canine ventricular papillary mus-
cles in the absence of any sympathetic agonist. Bars represent
meanSEM.
Figure 3. IKr and IKs in human ventricular myocytes in the
absence of any sympathetic agonist. A, Recordings in the
absence and presence of 10 mol/L chromanol 293B (left) or
100 nmol/L L-735,821 (right). Nisoldipine (1 mol/L) was used to
block inward calcium current (ICa) and E-4031 (5 mol/L) to
block IKr. Holding potential is 40 mV; pulse duration, 5000 ms;
and pulse frequency, 0.1 Hz. B, Recordings in the absence and
presence of 1 mol/L E-4031. Nisoldipine (1 mol/L) was used
to block ICa and L-735,821 (100 nmol/L) to block IKs. Holding
potential is 40 mV; pulse duration, 1000 ms; and pulse fre-
quency, 0.05 Hz.
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same potential at the same frequency, IKr was not substantially
changed (33.66.1 pA at 30mV and 128.117.4 pA at 40
mV; n8) (Figure 4D and 4F). This lack of effect of
increasing test pulse duration on IKr in human ventricular
myocytes was similar to that which we previously reported in
rabbit and dog. This failure to influence IKr occurred because
IKr activated completely and quickly before the end of either
the 150- or 500-ms test pulse. The magnitude of IKs, however,
was significantly increased when the test pulse duration was
increased from 150 to 500 ms (49.67.24 pA at 30 mV and
16.43.0 pA at 40 mV; n10). This increase in IKs
occurred because IKs activated slowly so that it continued to
activate beyond the shorter 150-ms test pulse duration (Figure
4E and 4F).
To determine the relative roles of IKs and of IKr under more
physiological conditions, we also compared their magnitudes
while applying an idealized ventricular muscle “action poten-
tial–like” test pulse. The test pulse used for these experiments
was obtained by digitizing a representative human right
ventricular action potential recorded using the conventional
microelectrode technique during continuous pacing at a cycle
length of 1000 ms. The waveform thus obtained arose from a
diastolic potential of 85 mV and was 115 mV in amplitude
with an APD90 of 300 ms, which roughly corresponds to a
normal human QT duration of 0.40 seconds at a heart rate of
70 bpm. A 40-ms-long prepulse to 40 mV was added
(Figure 5, inset) to the beginning of this idealized action
potential. When the IKr difference current (ie, the E-4031–
sensitive current) was measured during the idealized action
potential plateau, applied as a voltage-clamp test pulse, it was
small and increased in magnitude as the test voltage became
more negative (Figure 5). In contrast, IKs, measured as the
L-735,821–sensitive current, remained small throughout all
phases of the action potential–like test pulse (Figure 5).
Similar results were obtained in 4 additional human right
ventricular myocytes prepared from 3 additional normal
donor hearts. These results again indicate that the outward
current normally carried by IKr throughout the ventricular
action potential is considerably larger than that carried by IKs
in the absence of sympathetic agonists. These results are
consistent our finding that IKs block by chromanol 293B (10
mol/L), L-735,821 (100 nmol/L), or HMR-1556 (100
nmol/L and 1 mol/L) produces little effect on APD, whereas
IKr block by d-sotalol (30 mol/L) or E-4031 (1 mol/L)
greatly increased APD (Figure 1).
Effect of IKs Block During Increased Sympathetic
Activation After Attenuation of
Repolarization Reserve
The effect of 1 mol/L HMR-1556 was also tested in
preparations in the presence of 1 mol/L adrenaline and 50
nmol/L dofetilide. In these experiments, HMR-1556–induced
IKs block significantly lengthened APD (14.73.2%;
Figure 4. E-4031– (IKr; A) and L-735,821–
(IKs; B) sensitive currents in human ven-
tricular myocytes after application of a
short (150 ms) depolarizing test pulse to
30 mV from a holding potential of 40
mV in the absence of any sympathetic
agonist. Recordings of E-4031– (IKr; D)
and L-735,821– (IKs; E) sensitive currents
after a long (500 ms) depolarizing test
pulse to 30 mV from a holding potential
of 40 mV. Average IKr and IKs currents
at the end of short (150 ms; C) and long
(500 ms; F) depolarizing test pulses to 30
mV, and peak tail current at 40 mV.
Bars represent meanSEM.
Figure 5. E-4031– (1 mol/L) sensitive (IKr) and L-735,821– (100
nmol/L) sensitive (IKs) difference currents recorded during an
action potential–like test pulse in human ventricular myocytes in
the absence of any sympathetic agonist. The action potential–
like test pulse was obtained by recording a normal human ven-
tricular action potential with a conventional microelectrode in a
multicellular human papillary muscle preparation and adding a
50-ms prepulse from 80 to 40 mV. Similar results were
obtained in 4 additional myocytes.
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P0.05; n3; Figure 6). This effect is in sharp contrast to the
negligible effect of HMR-1556 on normal APD (Figures 1
and 2) and indicates that the effect of IKs on repolarization is
substantially increased when sympathetic activation is in-
creased and when a reduction in repolarization reserve results
in an abnormally long APD.
Discussion
Our results indicate that in isolated, multicellular ventricular
muscle obtained from normal, undiseased human hearts, chro-
manol 293B, L-735,821, and HMR-1556 did not markedly
increase action potential over a range of pacing cycle lengths
corresponding to heart rates of 12 to 200 bpm in the absence of
a sympathetic agonist. In addition, our studies indicate that the
concentrations of chromanol 293B and L-735,821 (10 mol/L
and 100 nmol/L, respectively) that failed to increase APD
significantly blocked IKs in ventricular myocytes isolated from
the same normal, undiseased human hearts. In contrast to these
findings, we demonstrated that E-4031 (1 mol/L) blocked IKr
and dramatically increased normal human ventricular muscle
APD, as did sotalol (30 mol/L), another recognized IKr blocker
that also dramatically increased human ventricular muscle APD
under the same conditions in which chromanol 293B and
L-735,821 failed.
The only study18 before this one to describe the effect of
chromanol on human ventricular action potential characteristics
was performed in right ventricular myocytes isolated from hearts
explanted from patients with end-stage heart failure. In that
study,18 1 to 10 mol/L chromanol 293B was reported to
significantly increased APD. However, when Schreieck et al19
examined the effects of 10 mol/L chromanol in guinea pig
ventricular muscle preparations, they found no effect on APD in
the absence of -adrenoceptor stimulation.19 When we previ-
ously examined the effects of chromanol 293B in rabbit13 and
dog11 ventricular papillary muscle preparations, 10 mol/L
chromanol 293B did not significantly increase APD. Our previ-
ous studies also demonstrated that the other IKs blocker,
L-735,821 (100 nmol/L), did not significantly affect APD in the
absence of a sympathetic agonist.
The explanation for these differences in results is unclear,
although some investigators20 have attributed them to differ-
ences between single-cell and multicellular preparations. Sun et
al,21 for instance, reported that higher chromanol concentrations
(30 to 100 mol/L) lengthened APD in perfused, multicellular
dog ventricular muscle “wedge” preparations. From this finding,
they speculated that chromanol is less able to diffuse into
multicellular preparations than into single cells and that its
effects are therefore less pronounced in multicellular prepara-
tions.22 Thus, this group argues20,21 that higher concentrations of
chromanol are necessary in multicellular ventricular prepara-
tions to achieve IKs block and to increase APD than are necessary
to completely block IKs in isolated myocytes. Other investigators
also suggested that, because of its physical and/or chemical
properties, L-735,821 poorly penetrates multicellular prepara-
tions but easily enters single myocytes (Dr J.J. Salata, unpub-
lished personal communication, 1998).
These explanations appear unlikely. In the present study in
human and in our previous studies in rabbit13 and dog11
ventricular muscle, a concentration of L-735,821 and HMR-
1556 that fully blocked IKs in single myocytes also failed to
increase APD in multicellular preparations, although
L-735,821 and HMR-1556 are reportedly more specific and
potent than chromanol 293B.23,24 In addition, the L-735,821
and HMR-1556 concentrations used in our experiments, 100
nmol/L and 1 mol/L, respectively, are reported to be 10
times their EC50 for IKs block.23,24 Furthermore, concentrations
of E-4031 and d-sotalol that block IKr in isolated myocytes
markedly increased APD in multicellular preparations; it
appears unlikely that either E-4031 or sotalol has distinctly
different abilities to penetrate multicellular preparations and
single myocytes than L-735,821.
On the other hand, Stengl et al14 and Volders et al25
recently obtained results similar to our finding that IKs block
Figure 6. Effect of 1 mol/L HMR-1556
on human ventricular action potentials
recorded in the presence of 50 nmol/L
dofetilide (DOF) and 1 mol/L adrenaline
(ADR). A, Representative action poten-
tials recorded at baseline (), after expo-
sure to 50 nmol/L dofetilide (‘) and 50
nmol/L dofetilide plus 1 mol/L adrena-
line (}), and after addition of 1 mol/L
HMR-1556 in the continued presence of
dofetilide and adrenaline (               ). B, Similar
effects on APD averaged in 3 experi-
ments. Bars show meanSEM; circles
represent each individual measurement.
C, Comparison of the effect of 1 mol/L
HMR-1556 on normal and on action
potentials recorded in the presence of
50 nmol/L dofetilide and 1 mol/L
adrenaline. The open bar indicates the
APD change observed after 1 mol/L
HMR-1556 in normal preparations; the
striated bar shows changes in APD
evoked by HMR-1556 in preparations in
which sympathetic activation was first
increased by 1 mol/L adrenaline and
repolarization reserve was reduced by 50 nmol/L dofetilide. Columns and error bars indicate meanSEM. *Significant changes (P005,
n3) between the conditions represented by the bars.
Jost et al Role of IKs in the Human Action Potential 1397
does not affect normal ventricular muscle APD in species
other than guinea pig in the absence of sympathetic stimula-
tion. They reported that, in both dog ventricular myocytes and
papillary muscle preparations, HMR-1556 (a highly selective
IKs blocker) failed to lengthen APD without prior sympathetic
simulation,14,25 even at high concentrations. These authors
concluded that IKs block–induced repolarization lengthening
requires an elevated degree of sympathetic tone as may occur
in the setting of heart failure. Others26 have suggested that the
sensitivity of APD shortening by IKs block is enhanced when
phosphorylation is increased as expected during increased
sympathetic nerve activity. Clearly, cAMP increases IKs and
may alter activation and deactivation kinetics for IKs. Thus, IKs
is expected to have different effects on APD when sympa-
thetic tone is increased. This relation between phosphoryla-
tion and the effects of IKs block on ventricular muscle APD
needs further investigation to better elucidate the importance
of sympathetic neural influences on electrogenesis in normal
and diseased human myocardium.
Nonetheless, our present findings clearly indicate that
neither chromanol 293B nor L-735,821 and HMR-1556
markedly affect normal human ventricular muscle APD over
a normal range of heart rates in the absence of sympathetic
stimulation. Thus, IKs in the absence of sympathetic neural
agonists plays little role in the repolarization of normal
ventricular muscle action potentials. Rather, in normal human
ventricular myocardium, IKr is the outward current most
responsible for termination of the action potential plateau and
initiation of final action potential repolarization. However, as
we have previously speculated, IKs may play a vital role in
normal myocardium when APD is prolonged as after a pause
in rhythm, decreased levels of thyroid hormone, or hypother-
mia. Some investigators suggest that IKs thus provides a
“repolarization reserve” when other outward repolarizing
currents are reduced, eg, by remodeling of ion currents during
heart failure progression.27,28 This role for IKs is supported by
the finding that specific IKs block markedly lengthens APD
after “repolarization reserve” is attenuated by IKr block with
50 nmol/L dofetilide. This observation is similar to that
previously reported in dog ventricular muscle.11,29
The lack of effect of IKs on normal APD now found in
human ventricular tissue in the absence of sympathetic
stimulation and previously reported in dog11,29 and rabbit13
occurs because IKs is relatively small compared with IKr over
the range of voltages encountered during the time course of
normal ventricular action potentials, and its activation is slow
compared with that of IKr in these species. Indeed we have
shown that, in normal human ventricular myocytes, IKr in the
absence of a sympathetic agonist activates rapidly
(31.07.4 ms; n6) during depolarizations to positive
potentials (30 mV) but deactivates slowly at 40 mV
(1599.953.9 ms; 26792.2875.6 ms; n8), whereas
IKs activates slowly at positive potentials (1005202.9 ms
at 30 mV; n7) and deactivates comparatively rapidly
(132.429.8 ms at 40 mV; n7) with respect to
diastolic intervals (300 to 700 ms) associated with physio-
logical heart rates.7,12
These kinetics for IKs and IKr activation and deactivation
indicate that, when APD is abnormally long or repolarization
reserves are attenuated and sympathetic activation is in-
creased, IKs block should be expected to substantially
lengthen APD while having little effect of normal APDs in
the absence of sympathetic stimulation. Expectations were
borne out when 10 mol/L chromanol 293B, 500 nmol/L
HMR-1556, or 100 nmol/L L-735,821 was applied to normal
dog ventricular muscle after APD was initially increased by
exposure to E-4031 and veratrine11 or by application of 100
nmol/L isoproterenol, which enhanced -receptor activation
and levels of intracellular cAMP.25
Clinical Implications
Inherited mutations in IKs channel protein encoding are
associated with the occurrence of LQT1,10,30 yet our findings
in normal human ventricular tissue in the absence of sympa-
thetic stimulation indicate that pharmacological IKs block is
not associated with an increase in APD, which is expected to
correlate with an increase in long-QT duration. These 2 facts
appear difficult to reconcile with one another, although it is
known that penetrance (ie, the number of individuals having
a particular genotype relative to those displaying the associ-
ated clinical phenotype) is rather low31,32 in families with
documented LQT1 mutations, histories of seizures, and sud-
den cardiac death. A far too simplistic explanation would be
that individuals with mutated IKs channel proteins and ele-
vated sympathetic tone lack the ability to compensate and
limit excessive APD lengthening as a result of other causes
such as extreme bradycardia, hypothyroidism, hypokalemia,
changes in autonomic neural influences, or exposure to drugs
affecting other repolarizing currents (eg, INa,slow, ICl, Ito, IKr,
IK1). Although this question is not directly addressed by the
study conducted, the results obtained suggest that if an
increase in QT duration is the basis for an increased risk of
arrhythmia and sudden cardiac death in people suffering from
long-QT syndrome, then therapeutic interventions that in-
crease “repolarization reserve” by any means should be
equally effective in reducing QT duration in all forms of the
long-QT syndrome.11,33,34 An adequately powered, prospec-
tive clinical trial is required to address such speculation.
The findings reported in this study suggest that antiarrhyth-
mic drugs that selectively block IKs are unlikely to affect
ventricular arrhythmias in the absence of sympathetic neural
stimulation. However, it must be recognized that sympathetic
tone is forever fluctuating in the in situ human heart, and
many believe that the selective IKs block in combination with
-adrenoceptor blockade should have antiarrhythmic benefit,
citing the clinical antiarrhythmic effectiveness of amiod-
arone, which has both IKs and -adrenoceptor blocking
properties during chronic administration.35 Nonetheless, an-
other little explored antiarrhythmic strategy might be to
increase, rather than to block, IKs. If IKs were increased (either
pharmacologically or genetically), arrhythmia risk might be
expected to be lowered; certainly, such an antiarrhythmic
intervention would benefit patients with inherited or acquired
long-QT syndrome. Therapeutic increases in IKs would in-
crease repolarization reserve and possibly reduce the risk of
sudden cardiac death during progression of heart failure when
IKr and Ito expression are downregulated.27,28,33,34
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Conclusions
We earlier reported that in dog and rabbit ventricular myocytes,
IKs plays no obvious role in altering action potential repolariza-
tion and QT duration at normal heart rates. In the present study,
in the absence of sympathetic stimulation, this finding is con-
firmed in isolated human ventricular preparations obtained from
the hearts of individuals without heart disease. These findings
should not be misconstrued as meaning that IKs does not play an
important role in the normal heart where sympathetic stimulation
is ever present and fluctuating continuously. We also believe that
IKs is vitally important in the normal heart where it prevents
excessive action potential prolongation in the setting of an
elevated sympathetic tone after a single long diastolic interval
after the compensatory pause that follows a premature ventric-
ular depolarization or during bradycardia or when APD is
prolonged by other means (eg, by unintentional IKr block,
hypothyroidism, or serum hypokalemia).
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